Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botox for Ureteral Stent Pain
NCT02078895Phase 3Terminated
- Sponsor
- University of California, Irvine
- Start
- Feb 2014
- Primary completion
- Feb 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of botulinum toxin type A in lower urinary tract symptoms (LUTS) (2 arms), sponsored by University of California, Irvine. Primary endpoint: Change in Lower Urinary Tract Discomfort at 2 weeks. Started Feb 2014; status: terminated.
02
Drugs
botulinum toxin type A
03
Conditions
lower urinary tract symptoms (LUTS)
Beyond the preview
Go deeper on NCT02078895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02078895.